Advertisement

Organisation › Details
Galapagos N.V. (Euronext + Nasdaq: GLPG)
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of GLPG0634. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2b studies in RA and in Phase 2 in Crohn’s disease. GLPG1205, a first-in-class inhibitor of GPR84, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690 is a compound that targets pulmonary diseases and is currently in a Phase 1 trial. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. *
![]() |
Start | 1999-06-01 established_pre |
Group | Galapagos (Group) | |
Predecessor | Galapagos Genomics N.V. | |
![]() |
Industry | genomics/genetics |
![]() |
Person | van de Stolpe, Onno (Galapagos 1999– CEO + Founder before IntroGene BV + Molecular Probes Europe BV) |
Person 2 | Filius, Bart (Galapagos 201412– CFO before Sanofi VP CFO at Sanofi Europe) | |
![]() |
Region | Mechelen |
Country | Belgium | |
Street | Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3 | |
City | 2800 Mechelen | |
Tel | +32-15342900 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | F: 1,001 to 5,000 (2019-12-31) |
Currency | EUR | |
Annual sales | 895,890,000 (revenues + other income, total, consolidated (2019) 2019-12-31) | |
Profit | 149,845,000 (2019-12-31) | |
Cash | 5,780,832,000 (2019-12-31) | |
* Document for �About Section�: | ||
Record changed: 2021-02-17 |
Advertisement

More documents for Galapagos (Group)
- [1] Galapagos N.V.. (2/10/21). "Press Release: Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF". Foster City, CA & Mechelen....
- [2] Galapagos N.V.. (12/15/20). "Press Release: Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca (filgotinib)". Foster City, CA & Mechelen....
- [3] Galapagos N.V.. (11/23/20). "Press Release: Selvita to Acquire Fidelta from Galapagos". Mechelen & Krakow....
- [4] Galapagos N.V.. (11/5/20). "Press Release: OncoArendi and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis". Mechelen & Warsaw....
- [5] Galapagos N.V.. (10/15/20). "Press Release: Galapagos and Servier Report Topline Results for ROCCELLA Phase 2 Clinical Trial with GLPG1972/S201086 in Knee Osteoarthritis Patients". Mechelen & Paris....
- [6] Galapagos N.V.. (8/19/20). "Press Release: Galapagos Announces that Gilead Received a Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis". Mechelen....
- [7] Galapagos N.V.. (8/12/20). "Press Release: Scipher Medicine and Galapagos Sign Collaboration in Inflammatory Bowel Disease". Mechelen & Boston, MA....
- [8] Galapagos N.V.. (4/16/20). "Press Release: Galapagos and Ryvu Announce Research Collaboration". Mechelen & Krakow....
- [9] Gilead Sciences, Inc.. (2/4/20). "Press Release: Gilead Sciences Announces Fourth Quarter and Full Year 2019 Financial Results". Foster City, CA....
- [10] Galapagos N.V.. (1/23/20). "Press Release: Galapagos Appoints Michele Manto as Chief Commercial Officer". Mechelen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top